Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence

Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence

BackgroundHepatocellular carcinoma (HCC) recurrence after liver transplantation is frequently multiple and extrahepatic, and with a poor prognosis. The therapeutic effects of current medications for post-transplant HCC recurrence are limited. This study assessed whether outcomes could be improved by...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wei-Chen Lee, Chih-Hsien Cheng, Tsung-Han Wu, Yu-Chao Wang, Jin-Chiao Lee, Hao-Chien Hung, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	DC dendritic cell hepatocellular carcinoma liver transplantation tyrosine kinase inhibitor immune checkpoint inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1589634/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
by: Vanda Salutari
Published: (2025-06-01)

Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery
by: Ping-Chung Tsai, et al.
Published: (2019-11-01)

Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis
by: Shuyun Wang, et al.
Published: (2024-10-01)

Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China
by: Ye Q, et al.
Published: (2025-08-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Mono‐TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study
by: Xue Yin, et al.
Published: (2025-03-01)

First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors
by: Yanjun Shen, et al.
Published: (2025-05-01)

Interdisciplinary approach to the management of patients with uterine cancer progression
by: K. Yu. Morkhov, et al.
Published: (2022-05-01)

Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma
by: Shengyuan Xu, et al.
Published: (2025-05-01)

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
by: Joohyun Hong, et al.
Published: (2024-03-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension
by: Wenze Wu, et al.
Published: (2025-08-01)

Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study
by: Xu-Wei Guo, et al.
Published: (2025-05-01)

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
by: Shasha Sun, et al.
Published: (2024-12-01)

Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven‐Year‐Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review
by: Aziz Eghbali, et al.
Published: (2025-08-01)

SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma
by: Xianglai Xu, et al.
Published: (2024-12-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
by: Junfeng Bu, et al.
Published: (2025-02-01)

Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis
by: Qibei Teng, et al.
Published: (2025-07-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines
by: Hyun-Min Ryu, et al.
Published: (2025-08-01)

Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2024-12-01)

Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma
by: Chunyu Lin, et al.
Published: (2025-06-01)

Transarterial intervention therapy plus systemic therapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Zelong Liu, et al.
Published: (2025-09-01)

Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapy
by: Yu-Wei Liu, et al.
Published: (2025-02-01)

Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengyu Tian, et al.
Published: (2025-04-01)

Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review
by: Vasile Gaborean, et al.
Published: (2025-06-01)

The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature
by: Abdulrahman Al‐Abdulmalek, et al.
Published: (2023-03-01)

Reversible hypopigmentation with pazopanib
by: B J Srinivasa, et al.
Published: (2018-01-01)

Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors
by: Nikhil Vojjala, et al.
Published: (2025-01-01)

Role of Immunotherapy in the Treatment of Hepatocellular Carcinoma
by: Irina Y. Dobrosotskaya, et al.
Published: (2025-04-01)

Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC
by: Bowen Liu, et al.
Published: (2025-07-01)

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas
by: Jinpeng Li, et al.
Published: (2025-08-01)

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas
by: Jinpeng Li, et al.
Published: (2025-08-01)

Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer
by: Leslie Cheng, et al.
Published: (2025-02-01)

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
by: Benjamin J. Lee, et al.
Published: (2024-10-01)

Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01)

Osteosarcoma: current insights and advances
by: Guraustin S. Brar, et al.
Published: (2025-06-01)

Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?
by: Hsiang-Wen Lin, et al.
Published: (2025-08-01)

Ponatinib-induced eruptive squamous cell carcinomas
by: Gabrielle Moore, MBE, MSc, et al.
Published: (2025-08-01)